Adiponectin: an Independent Risk Factor for Coronary Heart Disease in Men in the Framingham Offspring Study

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2011 Jul 12

PMID 21741045

Citations 32

Authors

Masumi Ai

Seiko Otokozawa

Bela F Asztalos

Charles C White

L Adrienne Cupples

Katsuyuki Nakajima

Stefania Lamon-Fava

Peter W Wilson

Yuji Matsuzawa

Ernst J Schaefer

Affiliations

Soon will be listed here.

Abstract

Objective: Our aim was to determine whether plasma adiponectin levels were an independent predictor of coronary heart disease (CHD) risk.

Methods And Results: Plasma adiponectin levels were measured in 3188 male and female participants from cycle 6 of the Framingham offspring Study (mean age: 57 years in both men and women; BMI: 28.5 kg/m(2) in men and 27.3 kg/m(2) in women), using a novel fully automated assay. Plasma adiponectin levels (median [25th percentile, 75th percentile]) were significantly higher in female than in male CHD-free subjects (14.8 [10.7,20.5] μg/ml versus 9.0 [7.0,12.2] μg/ml, p<0.001). Participants were followed for a mean of 7.5 years. After adjustment for age, BMI, smoking status, systolic blood pressure, treatment for hypertension, diabetes, use of cholesterol-lowering medication, total cholesterol level, high-density lipoprotein cholesterol level, and C-reactive protein levels, a higher plasma adiponectin level was a significant predictor of lower risk of future CHD events (n=117) in men (HR 0.49, p<0.0022). A similar trend was observed in women, but was no longer significant after multivariate adjustments.

Conclusions: Our data indicate that plasma adiponectin levels are an independent predictor of CHD in Caucasian men initially free of CHD.

Citing Articles

Sex difference in human diseases: mechanistic insights and clinical implications.

Shi Y, Ma J, Li S, Liu C, Liu Y, Chen J Signal Transduct Target Ther. 2024; 9(1):238.

PMID: 39256355 PMC: 11387494. DOI: 10.1038/s41392-024-01929-7.

G. Forst Intake Reduces the Cardiovascular Disease Plasmatic Markers Associated with a High-Fat Diet in a Mice Model.

Olivares-Caro L, Nova-Baza D, Radojkovic C, Bustamante L, Duran D, Mennickent D Antioxidants (Basel). 2023; 12(2).

PMID: 36829862 PMC: 9952125. DOI: 10.3390/antiox12020304.

Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors.

Meloni A, Cadeddu C, Cugusi L, Donataccio M, Deidda M, Sciomer S Int J Mol Sci. 2023; 24(2).

PMID: 36675097 PMC: 9864423. DOI: 10.3390/ijms24021588.

Is the Leptin/Adiponectin Ratio a Better Diagnostic Biomarker for Insulin Resistance than Leptin or Adiponectin Alone in Adolescents?.

Agostinis-Sobrinho C, Vicente S, Norkiene S, Rauckiene-Michaelsson A, Kievisiene J, Dubey V Children (Basel). 2022; 9(8).

PMID: 36010082 PMC: 9406389. DOI: 10.3390/children9081193.

Adipokines and coronary artery calcification in incident dialysis participants.

Roy N, Haddad D, Yang W, Rosas S Endocrine. 2022; 77(2):272-280.

PMID: 35751773 DOI: 10.1007/s12020-022-03111-x.

References

Matsuhisa M, Yamasaki Y, Emoto M, Shimabukuro M, Ueda S, Funahashi T . A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract. 2006; 77(1):151-4. DOI: 10.1016/j.diabres.2006.10.005. View

Westphal S, Borucki K, Taneva E, Makarova R, Luley C . Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2006; 193(2):361-5. DOI: 10.1016/j.atherosclerosis.2006.06.028. View

Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino L, DeFronzo R . Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89(9):4312-9. DOI: 10.1210/jc.2004-0190. View

Nishimura A, Sawai T . Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta. 2006; 371(1-2):163-8. DOI: 10.1016/j.cca.2006.03.008. View

Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T . Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis. 2006; 194(2):e43-51. DOI: 10.1016/j.atherosclerosis.2006.08.023. View

Lindsay R, Resnick H, Zhu J, Tun M, Howard B, Zhang Y . Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2005; 25(3):e15-6. DOI: 10.1161/01.ATV.0000153090.21990.8c. View

Sakamoto K, Sakamoto T, Ogawa H . The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther. 2006; 28(7):1012-21. DOI: 10.1016/j.clinthera.2006.07.001. View

Maahs D, Ogden L, Kinney G, Wadwa P, Snell-Bergeon J, Dabelea D . Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005; 111(6):747-53. DOI: 10.1161/01.CIR.0000155251.03724.A5. View

Phillips S, Ciaraldi T, Kong A, Bandukwala R, Aroda V, Carter L . Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003; 52(3):667-74. DOI: 10.2337/diabetes.52.3.667. View

10.

Wolk R, Berger P, Lennon R, Brilakis E, Davison D, Somers V . Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2006; 28(3):292-8. DOI: 10.1093/eurheartj/ehl361. View

11.

Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T . A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res. 2006; 47(7):1572-82. DOI: 10.1194/jlr.D600010-JLR200. View

12.

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H . Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102(11):1296-301. DOI: 10.1161/01.cir.102.11.1296. View

13.

Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Michael Wallace A . Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006; 114(7):623-9. DOI: 10.1161/CIRCULATIONAHA.106.618918. View

14.

Lawlor D, Davey Smith G, Ebrahim S, Thompson C, Sattar N . Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005; 90(10):5677-83. DOI: 10.1210/jc.2005-0825. View

15.

Kannel W, Feinleib M, MCNAMARA P, Garrison R, CASTELLI W . An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979; 110(3):281-90. DOI: 10.1093/oxfordjournals.aje.a112813. View

16.

Snijder M, Heine R, Seidell J, Bouter L, Stehouwer C, Nijpels G . Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care. 2006; 29(11):2498-503. DOI: 10.2337/dc06-0952. View

17.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

18.

Dekker J, Funahashi T, Nijpels G, Pilz S, Stehouwer C, Snijder M . Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008; 93(4):1489-96. DOI: 10.1210/jc.2007-1436. View

19.

Yang W, Jeng C, Wu T, Tanaka S, Funahashi T, Matsuzawa Y . Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002; 25(2):376-80. DOI: 10.2337/diacare.25.2.376. View

20.

Lamon-Fava S, Diffenderfer M, Barrett P, Buchsbaum A, Nyaku M, Horvath K . Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008; 28(9):1672-8. PMC: 2761712. DOI: 10.1161/ATVBAHA.108.164541. View